Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION In a company with a CMC site change mid-review, disproportionate reporting signal workbook is the evidence after a literature paper the 505(b)(2) package leans on getting retracted. Pediatric-plan strategist has to pick Proceed under protocol or Pause the pathway for this Pharma & Life Sciences CMC and Development Pathways close using disproportionate reporting signal workbook.

DECISION Pediatric-plan strategist in a company with a CMC site change mid-review must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using disproportionate reporting signal workbook after a literature paper the 505(b)(2) package leans on getting retracted.

HYPOTHESES TO TEST 1. A literature paper the 505(b)(2) package leans on getting retracted is noise around an already-controlled CMC and Development Pathways process in a company with a CMC site change mid-review, given disproportionate reporting signal workbook. 2. A literature paper the 505(b)(2) package leans on getting retracted is the event in disproportionate reporting signal workbook that forces Proceed under protocol for pediatric-plan strategist under Pharma & Life Sciences. 3. Disproportionate reporting signal workbook shows a one-file miss after a literature paper the 505(b)(2) package leans on getting retracted, not a CMC and Development Pathways program failure. 4. Disproportionate reporting signal workbook cannot decide to drop a secondary yet after a literature paper the 505(b)(2) package leans on getting retracted; hold is the only Pharma & Life Sciences close a company with a CMC site change mid-review can defend.

ANALYSIS REQUIRED 1. Check whether disproportionate reporting signal workbook supports the labeled claim pediatric-plan strategist would keep. 2. Map FDA-response timing and owner in a company with a CMC site change mid-review. 3. Trace CMC, labeling, or pharmacovigilance facts in disproportionate reporting signal workbook after a literature paper the 505(b)(2) package leans on getting retracted. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read disproportionate reporting signal workbook against a literature paper the 505(b)(2) package leans on getting retracted and write the one fact that would move to drop a secondary for pediatric-plan strategist.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (disproportionate reporting signal workbook after a literature paper the 505(b)(2) package leans on getting retracted). Lead with the Pharma & Life Sciences option disproportionate reporting signal workbook can support after a literature paper the 505(b)(2) package leans on getting retracted, then the two facts that force it, then the Monday action for pediatric-plan strategist in a company with a CMC site change mid-review.